Literature DB >> 19853645

Targeted drug delivery in pancreatic cancer.

Xianjun Yu1, Yuqing Zhang, Changyi Chen, Qizhi Yao, Min Li.   

Abstract

Effective drug delivery in pancreatic cancer treatment remains a major challenge. Because of the high resistance to chemo and radiation therapy, the overall survival rate for pancreatic cancer is extremely low. Recent advances in drug delivery systems hold great promise for improving cancer therapy. Using liposomes, nanoparticles, and carbon nanotubes to deliver cancer drugs and other therapeutic agents such as siRNA, suicide gene, oncolytic virus, small molecule inhibitor, and antibody has been a success in recent preclinical trials. However, how to improve the specificity and stability of the delivered drug using ligand or antibody directed delivery represent a major problem. Therefore, developing novel, specific, tumor-targeted drug delivery systems is urgently needed for this terrible disease. This review summarizes the current progress on targeted drug delivery in pancreatic cancer and provides important information on potential therapeutic targets for pancreatic cancer treatment. Copyright (c) 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19853645      PMCID: PMC2815202          DOI: 10.1016/j.bbcan.2009.10.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  92 in total

Review 1.  [Guidelines for management of patients with pancreatic cancer].

Authors:  Ingemar Ihse; Johan Permert; Roland Andersson; Anders Borgström; Sigmund Dawiskiba; Lars Krister Enander; Bengt Glimelius; Larsolof Hafström; Ulf Haglund; Jörgen Larsson; Gert Lindell; Anne Olmarker; Anette von Rosen; Joar Svanvik; Jan-Olof Svensson; Anders Thune; Karl Göran Tranberg
Journal:  Lakartidningen       Date:  2002-04-11

2.  Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.

Authors:  Asma Sultana; Catrin Tudur Smith; David Cunningham; Naureen Starling; John P Neoptolemos; Paula Ghaneh
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

3.  Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.

Authors:  Donald J Buchsbaum; James A Bonner; William E Grizzle; Murray A Stackhouse; Mark Carpenter; Daniel J Hicklin; Peter Bohlen; Kevin P Raisch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-11-15       Impact factor: 7.038

Review 4.  New target therapies in advanced pancreatic cancer.

Authors:  S Cascinu; L Verdecchia; N Valeri; R Berardi; M Scartozzi
Journal:  Ann Oncol       Date:  2006-05       Impact factor: 32.976

5.  Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma.

Authors:  M Löhr; A Hoffmeyer; J Kröger; M Freund; J Hain; A Holle; P Karle; W T Knöfel; S Liebe; P Müller; H Nizze; M Renner; R M Saller; T Wagner; K Hauenstein; W H Günzburg; B Salmons
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

Review 6.  Molecular targeting of pancreatic disorders.

Authors:  Kiichi Tamada; Xiao-Ping Wang; F Charles Brunicardi
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

7.  Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study.

Authors:  George P Stathopoulos; Teni Boulikas; Maria Vougiouka; George Deliconstantinos; Sotirios Rigatos; Eleftheria Darli; Vasiliki Viliotou; John G Stathopoulos
Journal:  Oncol Rep       Date:  2005-04       Impact factor: 3.906

8.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.

Authors:  K Chang; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

9.  Thermal ablation therapeutics based on CN(x) multi-walled nanotubes.

Authors:  Suzy V Torti; Fiona Byrne; Orla Whelan; Nicole Levi; Burak Ucer; Michael Schmid; Frank M Torti; Steven Akman; Jiwen Liu; Pulickel M Ajayan; Omkaram Nalamasu; David L Carroll
Journal:  Int J Nanomedicine       Date:  2007

Review 10.  Tumor targeting using liposomal antineoplastic drugs.

Authors:  Jörg Huwyler; Jürgen Drewe; Stephan Krähenbuhl
Journal:  Int J Nanomedicine       Date:  2008
View more
  24 in total

Review 1.  Chemoprevention strategies for pancreatic cancer.

Authors:  Silvia D Stan; Shivendra V Singh; Randall E Brand
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-05-04       Impact factor: 46.802

Review 2.  The Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear Structure.

Authors:  Gwen A Lomberk; Raul Urrutia
Journal:  Surg Clin North Am       Date:  2015-07-23       Impact factor: 2.741

3.  Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer.

Authors:  Navid Farr; Yak-Nam Wang; Samantha D'Andrea; Frank Starr; Ari Partanen; Kayla M Gravelle; Jeannine S McCune; Linda J Risler; Stella G Whang; Amy Chang; Sunil R Hingorani; Donghoon Lee; Joo Ha Hwang
Journal:  Int J Hyperthermia       Date:  2017-07-17       Impact factor: 3.914

4.  Combined AURKA and H3K9 Methyltransferase Targeting Inhibits Cell Growth By Inducing Mitotic Catastrophe.

Authors:  Angela Mathison; Ann Salmonson; Mckenna Missfeldt; Jennifer Bintz; Monique Williams; Sarah Kossak; Asha Nair; Thiago M de Assuncao; Trace Christensen; Navtej Buttar; Juan Iovanna; Robert Huebert; Gwen Lomberk
Journal:  Mol Cancer Res       Date:  2017-04-25       Impact factor: 5.852

5.  Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue.

Authors:  Aleksandra Karolak; Katarzyna A Rejniak
Journal:  Bull Math Biol       Date:  2018-02-08       Impact factor: 1.758

6.  Imaging-guided curative surgical resection of pancreatic cancer in a xenograft mouse model.

Authors:  Xiaoling Ni; Jingxuan Yang; Min Li
Journal:  Cancer Lett       Date:  2012-05-19       Impact factor: 8.679

7.  Triggered Nanoparticles as Therapeutics.

Authors:  Chang Soo Kim; Bradley Duncan; Brian Creran; Vincent M Rotello
Journal:  Nano Today       Date:  2013-08-01       Impact factor: 20.722

8.  Lipocalin-2 is associated with a good prognosis and reversing epithelial-to-mesenchymal transition in pancreatic cancer.

Authors:  Bin Xu; Da-Yong Jin; Wen-Hui Lou; Dan-Song Wang
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

9.  Application of albumin-based nanoparticles in the management of cancer.

Authors:  Xinzhe Yu; Chen Jin
Journal:  J Mater Sci Mater Med       Date:  2015-11-26       Impact factor: 3.896

10.  Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse.

Authors:  Guillermo Urrutia; Ann Salmonson; Jorge Toro-Zapata; Thiago M de Assuncao; Angela Mathison; Nelson Dusetti; Juan Iovanna; Raul Urrutia; Gwen Lomberk
Journal:  Mol Cancer Res       Date:  2019-12-10       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.